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Background: The Patient Reported Outcomes Measurement Information System 43-item short form (PROMIS-43)
and the five-level EQ-5D (EQ-5D-5L) are recently developed measures of health-related quality of life (HRQL) that
have potentially broad application in evaluating treatments and capturing burden of respiratory-related diseases.
The aims of this study were: (1) to examine their psychometric properties in patients with chronic obstructive pulmonary
disease (COPD), and (2) to identify dimensions of HRQL that differ and do not differ by lung function.
Methods: We conducted a multi-center, cross-sectional study (“COPD Outcomes-based Network for Clinical
Effectiveness & Research Translation” [CONCERT]). We analyzed patients who met spirometric criteria for COPD,
and completed EQ-5D-5L and PROMIS questionnaires. Disease severity was graded based on the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) classification. Pulmonary function test, PROMIS-43, EQ-5D (index
score and EQ-Visual Analog Scale [EQ-VAS]), six minute walk test (6MWT), and three dyspnea scales (mMRC, Borg,
FACIT-Dyspnea) were administered. Validity and reliability of EQ-5D-5L and PROMIS-43 were examined, and
differences in HRQL by GOLD grade were assessed.
Results: Data from 670 patients with COPD were analyzed (mean age 68.5 years; 58% male). More severe COPD
was associated with more problems with mobility, self-care and usual activities (all p-values <0.01) according to
EQ-5D-5L. Related domains on EQ-5D-5L, PROMIS and clinical measures were moderately (r = 0.30-0.49) to
strongly (r ≥ 0.50) correlated. A statistically significant trend of decreasing HRQL with more severe lung functions
was observed for EQ-5D-5L index scores, EQ-VAS scores, and PROMIS physical function and social roles.
Conclusions: Results supported the validity of EQ-5D-5L and PROMIS-43 in COPD patients, and indicate that
physical function and social activities decrease with level of lung function by GOLD grade, but not pain, mental
health, sleep or fatigue as reported by patients.
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Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of death worldwide, and affects 9-10%
of adults aged 40 years or older [1,2]. It is a slowly progres-
sive lung disease, characterized by chronic airway inflam-
mation and not fully reversible airflow obstruction [3].
Cigarette smoking is the main cause of COPD in developed
countries, and patients typically present with shortness of
breath, chronic cough and/or excessive sputum produc-
tion. In addition to a higher risk of mortality and morbid-
ity, COPD is associated with a substantial economic
burden of illness to the health care system [4-6].
The management of COPD is largely symptomatic, so
patient-reported outcomes (PROs) that evaluate health-
related quality of life (HRQL) are important to evaluating
the treatment and management of COPD. As COPD pro-
gresses, poor symptom control and exacerbations can lead
to limitations in functioning and impaired HRQL [7].
Disease-specific measures can provide insight into specific
aspects of HRQL, while generic HRQL measures have the
advantage of being able to compare across different pa-
tient populations but they may be less sensitive to changes
in HRQL compared to disease-specific measures [8,9].
Two generic HRQL measures, the Patient Reported
Outcomes Measurement Information System (PROMIS)
and EQ-5D-5L, were recently developed that have poten-
tial for broad use in evaluating COPD outcomes. PROMIS
is a health measurement system designed for a wide var-
iety of patient populations that utilizes banks of items be-
longing to specific domains of health [10]. The PROMIS
item banks were derived using item response theory (IRT)
and developed through a rigorous process of literature re-
view, focus groups across multiple diseases and sites, cog-
nitive assessments, and expert consultation. In addition,
fixed-length short forms, including the PROMIS-43, were
developed as an alternative computer-adaptive testing
(CAT). These short forms, while not providing as precise
measurement estimates as using CAT, cover core dimen-
sions of health from the PROMIS. Another measure, the
EQ-5D-5L, expanded the EQ-5D from 3 Levels to 5 Levels
in order to potentially improve upon the properties of the
standard 3-level EQ-5D by enhancing sensitivity and redu-
cing ceiling effects [11].
As few studies have examined these recently developed
measures in COPD, the aims of this study were: (1) to
examine their psychometric properties in patients with
COPD, and (2) to identify dimensions of HRQL that dif-
fer and do not differ by lung function.
Methods
Study design and subject recruitment
We conducted a secondary data analysis on COPD patients
who participated in a multi-center cross-sectional study
(NHLBI COPD Outcomes-based Network for ClinicalEffectiveness & Research Translation [CONCERT], https://
www.kpchr.org/concert/). The CONCERT investigators
developed a COPD Data Warehouse (CDW), containing
comprehensive information on more than 220,000 patients
with some indication of a chronic respiratory condition be-
tween 2006 and 2010. Seven U.S. clinical centers were in-
volved in patient recruitment: Kaiser Permanente Northwest
Region, VA Puget Sound Health Care System, University of
Chicago, University of Illinois Hospital and Health Sciences
System, University of Washington, Baystate Medical Center,
and University of North Carolina at Chapel Hill. Institutional
Review Board approval was received at each individual site
and at the Data Coordinating Center. A sample of patients
from the CDW were recruited for in-person evaluations and
a total of 1,206 patients (response rate 36%) participated and
completed the evaluations including spirometry, six-minute
walk test (6MWT), and extensive patient-reported outcomes
(dyspnea scores, quality of life, etc) (see Additional file 1 for
details on patient sampling and recruitment). Patients were
excluded if they could not perform a spirometry test or
could not participate due to cognitive impairment, frailty,
acute illness, receiving hospice care or staying in long-term
care facility, and issues related to geography, administration
or communication.
For the present study, patients fulfilling all the following
criteria were included: (1) having a diagnosis of COPD, de-
fined based on the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) spirometric criteria—a post-
bronchodilator FEV1/FVC (forced expiratory volume in
1 second/forced vital capacity) ratio <0.7 [3]; (2) ≥40 years
of age (as COPD mainly affects people over the age of 40
and the disease develops over decades of exposure to in-
haled particulates [12]); (3) with FEV1 percent predicted
available to indicate COPD disease severity; and (4) com-
pleted both EQ-5D-5L and PROMIS questionnaires.
Measures
Clinical and HRQL measures were administered to every
patient. Post-bronchodilator spirometry was utilized to
assess the extent of airflow limitation. Severity of COPD
was graded using percent predicted FEV1: GOLD 1 (mild) –
FEV1 ≥ 80% predicted, GOLD 2 (moderate) – 50% ≤
FEV1 < 80% predicted, GOLD 3 (severe) – 30% ≤ FEV1 < 50%
predicted, and GOLD 4 (very severe) – FEV1 < 30%
predicted [3].
The six minute walk test (6MWT) was administered to
assess patients’ functional capacity. The 6MWT measures
the distance (in meters) that an individual is able to walk
on a flat and hard floor over six minutes, referred to as the
6 minute walk distance (6MWD) [13]. Dyspnea scales
were used to quantify the degree of shortness of breath.
These included the modified Medical Research Council
(mMRC) dyspnea scale, Borg scale, and the Functional As-
sessment of Chronic Illness Therapy (FACIT)-Dyspnea
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more severe symptoms. The widely used mMRC dyspnea
scale is easy to administer, where patients indicate their
dyspnea level on a 5-point scale (0-4) by selecting the
physical tasks that provoke shortness of breath [14]. Borg
scale is another method of rating breathlessness, both at
rest and during the 6MWT (measuring exertional dyspnea),
on a scale of 0 to 10 [15]. The FACIT-Dyspnea short form
comprises 10 items that describe the experience of short-
ness of breath when doing a range of common tasks in the
past week, with each item scored on a 4-point rating scale
(from 0 [no shortness of breath] to 3 [severe shortness of
breath]) [16,17]. FACIT-Dyspnea scores are generated using
the T-score metric, where summary scores from responses
to items are transformed into a scale with a mean of 50 and
a standard deviation [SD] of 10 for patients with self-
reported COPD [18].
EQ-5D is a widely used preference-based measure that
includes a descriptive health self-classifier and a visual
analog scale (EQ-VAS) [19]. The classifier contains five
dimensions of health: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. The original
EQ-5D, which has 3 Levels (EQ-5D-3L) was recently
expanded to 5 Levels (EQ-5D-5L) for each single item
dimension of health. An index-based summary score for
the EQ-5D-5L can be generated using a recently published
crosswalk between the EQ-5D-5L descriptive system and
the EQ-5D-3L value sets [20]. This algorithm provides
index-based scores ranging from -0.109 to 1.0 in the U.S.
population, with lower values signifying worse health [21].
The EQ-VAS asks the patient to rate their own health on
a scale ranging from 0 (worst imaginable health) to 100
(best imaginable health) [19].
The PROMIS-43 short form, a multi-dimensional 43-
item generic measure of health, is intended for use across
a variety of conditions. It includes seven domains: physical
function, anxiety, depression, fatigue, sleep disturbance,
pain interference, and satisfaction with participation in so-
cial roles, as well as a pain intensity item scored from 0 to
10. There are 6 items in each of the seven domains, with
responses ranging from 1 to 5. Raw scores for each do-
main are calculated by summing the item scores while
adjusting for missing item responses, and it can be esti-
mated if at least 4 out of the 6 items in that domain were
answered. Raw scores are transformed using the T-score
metric based on the item response theory calibrations in
which scores have a mean of 50 and a SD of 10 for the
general population in the U.S. [22,23]. T-scores can be es-
timated using the scoring tables listed in the PROMIS
manuals [24]. A higher PROMIS T-score implies more of
the concept being measured; for instance, a higher PRO-
MIS score on physical function indicates better function-
ing, whereas a higher score on depression indicates more
severe depressive symptoms.Statistical analysis
The psychometric properties of EQ-5D-5L and PROMIS-
43 were examined in terms of reliability, convergent valid-
ity, and discriminative ability. Internal consistency reliability
of the PROMIS domains was evaluated using Cronbach’s
alpha. The distribution of responses to the EQ-5D-5L were
described, and Chi-square or Fisher’s exact tests were per-
formed to assess the ability of EQ-5D dimensions to discern
among COPD patients with different grades of airflow
limitation.
Convergent construct validity was evaluated by assessing
the strength of associations among the PROMIS do-
mains, EQ-5D measures (summary and dimension scores),
and other clinical or functional status measures using
Spearman’s rank correlation coefficients (rs). Correlation
coefficients were interpreted as follows: rs < 0.10 (absent),
rs = 0.10-0.29 (weak), rs = 0.30-0.49 (moderate), and rs ≥
0.50 (strong) [25]. We hypothesized that strong correlations
would be observed between related domains of health on
the EQ-5D-5L and PROMIS, i.e. mobility and physical
functioning; usual activities and social roles; pain/discom-
fort and pain interference; anxiety/depression and anxiety
and depression, respectively.
One-way analysis of variance (ANOVA) was used to
compare the EQ-5D, EQ-VAS, PROMIS domains, and
other measures among patients with different GOLD
grades. ANOVA F-statistics comparing mean scores across
GOLD grades were used to assess the relative discrimina-
tive ability of the EQ summary scores (index score, VAS)
and the PROMIS-43 subscales. Relative statistical effi-
ciency (RE) was compared, defined as the ratio of the
ANOVA F-statistics for a given measure and the FACIT-
Dyspnea score, which served as the reference measure
[26-28]. Although ANOVA is robust to moderate devia-
tions from normality [29], non-parametric Kruskal-Wallis
tests were also performed. All statistical analyses were car-
ried out using the Statistical Analysis System (SAS), version
9.2 (SAS Institute, Cary, NC). All p-values were reported,
and for purposes of interpretation, p-values <0.01 were
considered statistically significant.
Results
A total of 670 patients were included in our analysis. The
mean age was 68.5 (SD 10.4) years, with 58% men and 78%
self-identified as caucasian (Table 1). Most patients were
current (n = 193, 28.8%) or past (n = 412, 61.5%) smokers,
with an average of 44.2 (SD 31.2) pack-years. The study
subjects were divided into 4 groups based on the severity of
airflow limitation: mild (GOLD 1, n = 102), moderate
(GOLD 2, n = 353), severe (GOLD 3, n = 165) and very se-
vere (GOLD 4, n = 50). Patients included as GOLD 3 and 4
(with more severe disease) were significantly younger, more
likely to be African-American, have lower education level,
less household income, heavier smoking history, and less
Table 1 Patient demographic and clinical characteristics (Total N = 670)
Characteristic, n (%) No. of missing Total sample GOLD 1
(Mild; n = 102)
GOLD 2
(Moderate; n = 353)
GOLD 3
(Severe; n = 165)
GOLD 4
(Very severe; n = 50)
p-value (comparing
GOLD 1,2 vs 3,4)
Age, mean (SD) 0 68.5 (10.4) 72.1 (11.3) 68.3 (10.5) 67.7 (9.7) 65.1 (7.4) 0.02§
Male 0 387 (57.8) 69 (67.7) 203 (57.5) 88 (53.3) 27 (54.0) 0.12†
Race 0 <.0001‡
Caucasian 524 (78.2) 91 (89.2) 290 (82.2) 114 (69.3) 29 (58.0)
African American 121 (18.1) 11 (10.8) 52 (14.7) 40 (24.1) 18 (36.0)
Native American* 20 (3.0) 0 (0) 8 (2.3) 9 (5.4) 3 (6.0)
Asian/multiracial/other 5 (0.8) 0 (0) 3 (0.9) 2 (1.2) 0 (0)
BMI (Kg/m2), mean (SD) 4 29.1 (7.6) 29.1 (6.2) 29.4 (7.0) 29.4 (8.9) 26.0 (9.3) 0.26§
Main activity 0 0.30†
Employed (incl.self-employment) 106 (15.8) 18 (17.7) 61 (17.3) 20 (12.1) 7 (14.0)
Retired 451 (67.3) 69 (67.7) 234 (66.3) 114 (69.1) 34 (68.0)
Keeping house/student/seeking work 61 (9.1) 10 (9.9) 31 (8.8) 17 (10.3) 3 (6.0)
Disabled – on disability 41 (6.1) 5 (4.9) 22 (6.2) 8 (4.9) 6 (12.0)
Other 11 (1.6) 0 (0) 5 (1.4) 6 (3.6) 0 (0)
Education 0 0.04†
Some high school or less 92 (13.7) 12 (11.8) 48 (13.6) 27 (16.4) 5 (10.0)
High school graduate or GED 178 (26.6) 23 (22.6) 97 (27.5) 44 (26.7) 14 (28.0)
Vocational college or some college 256 (38.2) 36 (35.3) 126 (35.7) 70 (42.4) 24 (48.0)
College degree 86 (12.8) 14 (13.7) 53 (15.0) 16 (9.7) 3 (6.0)
Professional or graduate degree 58 (8.7) 17 (16.7) 29 (8.2) 8 (4.9) 4 (8.0)
Household total gross yearly income 77 0.002†
Less than $30,000 275 (46.4) 30 (36.1) 137 (43.5) 86 (57.3) 22 (48.9)
$30,001 to $50,000 164 (27.7) 25 (30.1) 94 (29.8) 33 (22.0) 12 (26.7)
$50,001 to $75,000 82 (13.8) 14 (16.9) 39 (12.4) 23 (15.3) 6 (13.3)
Over $75,000 72 (12.1) 14 (16.9) 45 (14.3) 8 (5.3) 5 (11.1)
Smoking status 0 0.09†
Current smoker 193 (28.8) 21 (20.6) 109 (30.9) 49 (29.7) 14 (28.0)
Past smoker 412 (61.5) 64 (62.8) 209 (59.2) 104 (63.0) 35 (70.0)
Never smoker 65 (9.7) 17 (16.7) 35 (9.9) 12 (7.3) 1 (2.0)
Smoke pack-years, mean (SD) 2 44.2 (31.2) 36.3 (30.3) 44.2 (30.9) 48.0 (31.5) 48.2 (31.8) 0.03§
Comorbid medical conditions
Coronary heart disease** 0 220 (32.8) 42 (41.2) 119 (33.7) 51 (30.9) 8 (1.2) 0.04†
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Table 1 Patient demographic and clinical characteristics (Total N = 670) (Continued)
Hypertension 0 416 (62.1) 57 (55.9) 221 (62.6) 110 (66.7) 28 (56.0) 0.44†
Diabetes 0 154 (23.0) 20 (19.6) 85 (24.1) 39 (23.6) 10 (20.0) 0.93†
Stroke or cerebrovascular disease 0 96 (14.3) 13 (12.8) 53 (15.0) 25 (15.2) 5 (10.0) 0.85†
Cancer history 0 174 (26.0) 22 (21.6) 96 (27.2) 44 (26.7) 12 (24.0) 0.98†
Dementia 0 10 (1.5) 2 (2.0) 7 (2.0) 1 (0.6) 0 (0) 0.18‡
Depression 0 229 (34.2) 34 (33.3) 131 (37.1) 52 (31.5) 12 (24.0) 0.10†
GED = general education diploma.
Based on †Chi-square, or ‡Fisher’s exact test or §t-test.
*Inclde American Indian, Alaskan Native, Native Hawaiian, Pacific Islander, Native American plus other.
**Include angina, coronary artery disease, coronary artery revascularization, or myocardial infarction diagnosed by doctor.
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with mild to moderate disease (p < 0.05) (Table 1).
All levels of the EQ-5D-5L were utilized by the overall
cohort, but only a relatively small proportion of patients
reported severe or extreme problems on each dimension
(range 1.4-8.7%) (Table 2). More than 50% of patients re-
ported no problems with self-care and anxiety/depres-
sion (in all COPD grades) and usual activities (GOLD 1
only). More severe COPD was associated with signifi-
cantly more problems with mobility, self-care and usual
activities (p < 0.01). Approximately 30% of all COPDTable 2 EQ-5D-5L profile of patients by GOLD grade
Total sample
[n (%)]
GOLD 1
(mild; n = 102)
[n (%)]
GOLD 2
(moderate; n
[n (%)]
EQ-5D dimension
Mobility
No problems 244 (36.4) 44 (43.1) 141 (39.9
Slight problems 179 (26.7) 28 (27.5) 93 (26.4)
Moderate problems 189 (28.2) 25 (24.5) 92 (26.1)
Severe problems 52 (7.8) 5 (4.9) 25 (7.1)
Extreme problems 6 (0.9) 0 (0) 2 (0.6)
Self-care
No problems 539 (80.5) 87 (85.3) 297 (84.1
Slight problems 88 (13.1) 13 (12.8) 43 (12.2)
Moderate problems 34 (5.1) 2 (2.0) 9 (2.6)
Severe problems 5 (0.8) 0 (0) 4 (1.1)
Extreme problems 4 (0.6) 0 (0) 0 (0)
Usual activities
No problems 303 (45.2) 61 (59.8) 175 (49.6
Slight problems 183 (27.3) 22 (21.6) 96 (27.2)
Moderate problems 135 (20.2) 13 (12.8) 64 (18.1)
Severe problems 32 (4.8) 4 (3.9) 12 (3.4)
Extreme problems 17 (2.5) 2 (2.0) 6 (1.7)
Pain/discomfort
No problems 255 (38.1) 35 (34.3) 131 (37.1
Slight problems 207 (30.9) 33 (32.4) 118 (33.4
Moderate problems 160 (23.9) 27 (26.5) 81 (23.0)
Severe problems 43 (6.4) 7 (6.9) 21 (6.0)
Extreme problems 5 (0.8) 0 (0) 2 (0.6)
Anxiety/depression
No problems 427 (63.7) 63 (61.8) 237 (67.1
Slight problems 139 (20.8) 20 (19.6) 64 (18.1)
Moderate problems 79 (11.8) 16 (15.7) 40 (11.3)
Severe problems 20 (3.0) 2 (2.0) 11 (3.1)
Extreme problems 5 (0.8) 1 (1.0) 1 (0.3)
GOLD = Global initiative for chronic Obstructive Lung Disease.
Based on †Chi-square, or ‡Fisher’s exact test.patients reported at least moderate pain/discomfort and
15% reported at least moderate anxiety/depression, but dif-
ferences across COPD grades were not significant (p = 0.26
and p = 0.15, respectively). The response of ‘11111’ (no
problems in any dimension) was reported in a dimishing
proportion of respondents as grades got more severe: 19.6%
(GOLD 1), 18.4% (GOLD 2), 11.5% (GOLD 3), and 4%
(GOLD 4). Overall, the mean (SD) score was 0.79 (0.15) for
the EQ-5D index, and 70.6 (19.6) for the EQ-VAS (Table 3).
When stratified by GOLD grade, EQ-5D index-based
mean scores ranged from 0.81 (GOLD 1) to 0.74 (GOLD 4)= 353)
GOLD 3
(severe; n = 165)
[n (%)]
GOLD 4
(very severe; n = 50)
[n (%)]
p-value
(comparing GOLD
1,2 vs 3,4)
0.003†
) 41 (24.9) 18 (36.0)
46 (27.9) 12 (24.0)
58 (35.2) 14 (28.0)
16 (9.7) 6 (12.0)
4 (2.4) 0 (0)
<.0001‡
) 127 (77.0) 28 (56.0)
23 (13.9) 9 (18.0)
11 (6.7) 12 (24.0)
0 (0) 1 (2.0)
4 (2.4) 0 (0)
<.0001†
) 56 (33.9) 11 (22.0)
49 (29.7) 16 (32.0)
44 (26.7) 14 (28.0)
10 (6.1) 6 (12.0)
6 (3.6) 3 (6.0)
0.26†
) 62 (37.6) 27 (54.0)
) 48 (29.1) 8 (16.0)
42 (25.5) 10 (20.0)
11 (6.7) 4 (8.0)
2 (1.2) 1 (2.0)
0.15†
) 101 (61.2) 26 (52.0)
41 (24.9) 14 (28.0)
15 (9.1) 8 (16.0)
5 (3.0) 2 (4.0)
3 (1.8) 0 (0)
Table 3 Patient clinical and HRQL measurements
Measure No. of
missing
Total sample
[Mean (SD)]
GOLD 1 (n = 102)
[Mean (SD)]
GOLD 2 (n = 353)
[Mean (SD)]
GOLD 3 (n = 165)
[Mean (SD)]
GOLD 4 (n = 50)
[Mean (SD)]
ANOVA RE
ratio
ANOVA Kruskal-Wallis test
F-stat p-value p-value
FACIT-Dyspnea 6 44.6 (8.4) 41.0 (7.9) 43.3 (8.0) 47.6 (8.0) 51.6 (6.9) 31.19 Ref <.0001 <.0001
mMRC dyspnea 60 1.50 (0.99) 1.20 (0.95) 1.38 (0.95) 1.79 (0.95) 1.88 (1.06) 11.71 0.38 <.0001 <.0001
Borg dyspnea (at rest) 55 0.67 (1.08) 0.55 (0.91) 0.60 (1.07) 0.92 (1.19) 0.64 (0.97) 3.52 0.11 0.01 0.02
Borg dyspnea (during 6MWT) 60 2.52 (1.94) 2.07 (1.73) 2.27 (1.90) 3.02 (1.78) 3.78 (2.37) 13.06 0.42 <.0001 <.0001
6MWD 60 335.6 (110.4) 371.9 (111.2) 345.5 (109.4) 301.2 (103.1) 297.8 (101.3) 11.24 0.36 <.0001 <.0001
EQ-5D index 0 0.79 (0.15) 0.81 (0.14) 0.81 (0.14) 0.76 (0.17) 0.74 (0.15) 6.13 0.20 0.0004 0.002
EQ-VAS 0 70.6 (19.6) 76.6 (17.5) 72.6 (19.1) 65.7 (20.2) 61.1 (19.7) 12.24 0.39 <.0001 <.0001
PROMIS
Physical function (P-PF) 0 40.6 (7.6) 43.2 (8.2) 41.7 (7.7) 38.3 (6.0) 35.3 (5.5) 21.41 0.69 <.0001 <.0001
Anxiety (P-A) 0 49.7 (9.2) 49.5 (9.6) 49.3 (9.0) 50.0 (9.4) 52.3 (8.7) 1.69 0.05 0.17 0.15
Depression (P-D) 0 48.3 (9.3) 49.3 (10.1) 47.3 (8.8) 48.5 (9.6) 51.8 (8.9) 4.08 0.13 0.007 0.01
Fatigue (P-F) 0 50.8 (9.2) 51.2 (9.9) 50.0 (9.2) 51.3 (8.8) 53.9 (8.4) 3.01 0.10 0.03 0.04
Sleep disturbance (P-SD) 0 49.8 (9.4) 51.5 (10.2) 49.3 (9.0) 50.0 (9.6) 48.9 (9.4) 1.64 0.05 0.18 0.23
Social roles (P-SR) 2 48.1 (9.3) 49.3 (9.0) 49.0 (9.4) 46.3 (9.3) 44.7 (7.9) 6.07 0.19 0.0004 0.001
Pain interference (P-PI) 3 53.9 (9.6) 53.8 (9.5) 54.3 (9.5) 53.3 (9.7) 53.1 (9.8) 0.56 0.02 0.64 0.74
Pain intensity scale (P-P) 0 3.49 (2.67) 3.49 (2.69) 3.54 (2.62) 3.43 (2.70) 3.28 (2.90) 0.18 0.01 0.91 0.85
6MWD = six-minute walk distance; 6MWT = six-minute walk test; ANOVA = analysis of variance; GOLD = Global initiative for chronic Obstructive Lung Disease; FACIT = Factional Assessment of Chronic Illness Therapy;
mMRC =modified Medical Research Council; PROMIS = Patient Reported Outcomes Measurement Information System; RE = relative efficiency; ref = reference group (RE = 1).
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http://www.biomedcentral.com/1471-2288/14/78(p-value = 0.004), and EQ-VAS mean scores ranged from 76.6
(GOLD 1) to 61.1 (GOLD 4) (p-value < 0.001). Patients
with more severe COPD had lower mean EQ-5D index
scores and EQ-VAS scores, although the index-based score
did not discriminate between the milder grades of COPD.
Regarding PROMIS-43, physical function had a overall
mean score of 40.6 (SD 7.6), and for the rest of domains,
the mean scores ranged from 48.1 (social roles) to 53.9
(pain interference) (Table 3). The mean pain intensity
score was 3.49 (SD 2.67) on a scale of 0 to 10. The PRO-
MIS physical function, depression, fatigue, and social roles
had p-values <0.05, but only physical function and social
roles demonstrated a statistically significant decline that
was monotonically associated with decreasing lung func-
tion (Table 3). No differences in mean scores by GOLD
grade were observed for the PROMIS domains of anxiety,
sleep disturbance, pain interference and pain intensity.
About sixty patients refused or did not complete the
6MWT and/or dyspnea severity assessment due to health
issues (e.g., wheelchair or walker dependent, body pain, dis-
comfort while doing the test). All the dyspnea measures
and 6MWD demonstrated discriminative ability when
mean scores were compared among subgroups with differ-
ent levels of COPD severity (Table 3). The FACIT-Dyspnea
provided the highest relative efficiency (RE) to discriminate
among subgroups of COPD severity, followed by PROMIS
physical function, Borg dyspnea during 6MWT, EQ-VAS,
mMRC dyspnea, 6MWD, and EQ-5D index .
Cronbach’s alpha for PROMIS domains ranged from 0.89
to 0.95, demonstrating acceptable internal consistency reli-
ability [30]. Strong correlations between related domains on
the EQ-5D-5L and PROMIS-43 were observed as expected
(Table 4). EQ-5D usual activities (EQ-UA) showed strong
correlations with the PROMIS physical function (P-PF)
(rs = -0.65), fatigue (P-F) (rs = 0.54), and social roles (P-SR)
(rs= -0.55), and moderate correlations with the rest of
PROMIS domains. EQ-5D pain/discomfort (EQ-PD) was
strongly correlated with PROMIS pain interference (P-PI)
and pain intensity (P-P) (rs = 0.67 and 0.63, respectively),
and the EQ-5D anxiety/depression (EQ-AD) with PROMIS
anxiety (P-A) and depression (P-D) (rs = 0.60 and 0.59, re-
spectively). EQ-5D mobility (EQ-MO) was moderately to
strongly related to four domains of the PROMIS (physical
function [P-PF], fatigue [P-F], social roles [P-SR], and pain
interference [P-PI]) and the pain intensity item (P-P). The
EQ-5D dimension of self-care (EQ-SC) was moderately cor-
related with P-PF and P-SR.
In examining the relationship between clinical measures
and the EQ-5D index, EQ-VAS, PROMIS subscales, only
the FACIT-Dyspnea and the PROMIS physical function
(P-PF) showed at least moderate correlations with % of
predicted FEV1 (rs = -0.36 and 0.32, respectively) (Table 5).
EQ-5D index scores and VAS scores were both mo-
derately to strongly correlated with PROMIS domains,dyspnea scales, and the 6MWD, but the magnitude of
these correlations was smaller with EQ-VAS scores than
EQ-5D index scores. All subscales of PROMIS-43 had
moderate to strong correlations with at least one of the
dyspnea scores. Among all the HRQL measures, the PRO-
MIS physical function (P-PF), fatigue (P-F), social roles (P-
SR), EQ-5D index and EQ-VAS, in general, had stronger
correlations with the symptom severity. All measures were
at least (or nearly) moderately correlated with 6MWD, ex-
cept for PROMIS anxiety (P-A), depression (P-D) and
sleep disturbance (P-SD) (absolute r <0.3).
Discussion
Our study results provide evidence to support the validity
of two recently developed generic measures of HRQL,
EQ-5D-5L and PROMIS-43, in COPD. The convergent
construct validity of the two measures was supported by
the moderate to strong correlations between related do-
mains, and between the domain and summary scores of
the generic measures and the dyspnea measures. EQ-5D-
5L index, EQ-VAS, and two domains of PROMIS (physical
function and social roles) had higher RE ratios among the
HRQL measures, suggesting that these scores provide
greater statistical power (discriminative ability) to capture
differences in HRQL in relation to disease severity as mea-
sured by lung function.
Level of dyspnea is a strong predictor for health status
[31-33]. Both EQ-5D and PROMIS had moderate associa-
tions with at least one measure of dyspnea, with the corre-
lations varying across the PROMIS-43 subscales. Our
results concur with previous reports that spirometric pa-
rameters (% of predicted FEV1), unlike severity of breath-
lessness, does not correlate well with HRQL [31,32,34,35].
While lung function test with spirometry serves as an im-
portant clinical tool to measure the degree of airflow limi-
tation, a number of studies have demonstrated that it
provides an incomplete assessment of health burden to
the patient, which can include physical and psychosocial
functioning. This discernment coincides with the new
COPD assessment tool recently proposed by the GOLD,
which recommends evaluation of COPD based on not
only lung function, but also the assessment of symptoms
and exacerbation risk [3]. This also reinforces the import-
ance of evaluating patient-reported outcomes along with
clinical measures (e.g., lung function test) when gauging
the effect of health interventions.
COPD severity has been shown to influence the degree
of physical disability, impairing the ability to perform activ-
ities of daily living, and contributing to poor HRQL [36].
Patients with COPD had relatively worse self-rated HRQL
in multiple PROMIS domains as compared with individuals
without COPD or any condition [37]. The negative impact
of COPD is more pronounced on the physical aspect of
health than on the mental component [31]. Consistent with
Table 4 Correlations between domains of EQ-5D-5L and PROMIS-43 (all with p <0.001)
EQ-MO EQ-SC EQ-UA EQ-PD EQ-AD P-PF P-A P-D P-F P-SD P-SR P-PI
EQ-MO 1
EQ-SC 0.39 1
EQ-UA 0.52 0.45 1
EQ-PD 0.47 0.23 0.38 1
EQ-AD 0.26 0.22 0.38 0.34 1
P-PF -0.65 -0.46 -0.65 -0.40 -0.34 1
P-A 0.23 0.21 0.34 0.29 0.60 -0.40 1
P-D 0.28 0.26 0.37 0.30 0.59 -0.44 0.78 1
P-F 0.41 0.27 0.54 0.40 0.41 -0.62 0.53 0.59 1
P-SD 0.20 0.15 0.34 0.28 0.32 -0.34 0.41 0.45 0.55 1
P-SR -0.44 -0.34 -0.55 -0.32 -0.37 0.65 -0.45 -0.49 0.61 -0.42 1
P-PI 0.46 0.23 0.44 0.67 0.35 -0.52 0.42 0.43 0.57 0.41 -0.47 1
P-P 0.40 0.19 0.34 0.63 0.32 -0.43 0.39 0.38 0.45 0.41 -0.40 0.79
EQ-MO = EQ-Mobility; EQ-SC = EQ-Self-Care; EQ-UA = EQ-Usual Activities; EQ-PD = EQ-Pain/Discomfort; EQ-AD = EQ-Anxiety/Depression; PROMIS = Patient Reported
Outcomes Measurement Information System; P-PF = PROMIS-Physical Function; P-A = PROMIS-Anxiety; P-D = PROMIS-Depression; P-F = PROMIS-Fatigue; P-SD =
PROMIS-Sleep Disturbance; P-PI = PROMIS-Pain Interference; P-P = PROMIS-Pain intensity scale; P-SR = PROMIS-Satisfaction with participation in Social Roles.
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http://www.biomedcentral.com/1471-2288/14/78the study by Gonzalez-Moro and colleagues [36], our find-
ings suggest that, in general, physical functioning tends to
be affected in all grades of COPD patients while mental
health is impaired only in patients at more severe stages.
The mean scores of PROMIS domains indicated that phys-
ical function, among all the domains measured in the PRO-
MIS, was the aspect of health status most affected byTable 5 Correlations between clinical and HRQL measures
% pred. FEV1 FACIT-
Dyspnea
mMRC
dyspnea
B
(
% pred. FEV1 1
FACIT-dyspnea -0.36 1
mMRC dyspnea -0.29 0.59 1
Borg dyspnea (at rest) -0.13 0.46 0.33
Borg dyspnea (during 6MWT) -0.26 0.56 0.48
6MWD 0.28 -0.44 -0.45
EQ-5D index 0.19 -0.58 -0.48
EQ-VAS 0.26 -0.43 -0.41
P-PF 0.32 -0.71 -0.62
P-A -0.09 0.42 0.23
P-D -0.08 0.45 0.25
P-F -0.09 0.58 0.43
P-SD 0.02† 0.35 0.28
P-SR 0.18 -0.57 -0.41
P-PI -0.01† 0.41 0.33
P-P 0.01† 0.35 0.26
6MWD = six-minute walk distance; 6MWT = six-minute walk test; FACIT = Factional A
1 second; mMRC =modified Medical Research Council; PROMIS = Patient Reported O
P-A = PROMIS-Anxiety; P-D = PROMIS-Depression; P-F = PROMIS-Fatigue; P-SD = PRO
intensity scale; P-SR = PROMIS-Satisfaction with participation in Social Roles.
†Spearman’s rank correlation coefficient p > 0.05 (not significant).COPD; physical function was considerably impaired even
in patients with mild COPD, as the mean domain score of
PROMIS physical function in patients with GOLD grade 1
was less than 50 (the mean score of the general population).
The mean domain scores of PROMIS anxiety and depres-
sion were higher than 50 only in patients with very severe
COPD (i.e. GOLD 4).org dyspnea
at rest)
Borg dyspnea
(during 6MWT)
6MWD EQ-5D index EQ-VAS
1
0.36 1
-0.25 -0.34 1
-0.38 -0.37 0.46 1
-0.34 -0.35 0.29 0.55 1
-0.39 -0.58 0.56 0.68 0.51
0.27 0.23 -0.19 -0.46 -0.33
0.26 0.29 -0.19 -0.49 -0.34
0.38 0.42 -0.29 -0.55 -0.48
0.26 0.23 -0.10 -0.37 -0.31
-0.37 -0.42 0.37 0.54 0.47
0.31 0.22 -0.29 -0.65 -0.37
0.27 0.21 -0.29 -0.58 -0.33
ssessment of Chronic Illness Therapy; FEV1 = forced expiratory volume in
utcomes Measurement Information System; P-PF = PROMIS-Physical Function;
MIS-Sleep Disturbance; P-PI = PROMIS-Pain Interference; P-P = PROMIS-Pain
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http://www.biomedcentral.com/1471-2288/14/78Evidence on the properties of the EQ-5D-5L is only be-
ginning to emerge. The first paper was a multi-country
study by Janssen et al. in 2012 that compared the measure-
ment properties of the 5-level and 3-level EQ-5D, includ-
ing 342 patients with respiratory disease (COPD or
asthma) as one of the eight patient groups with chronic
conditions [38]. The 5-level EQ-5D descriptive system
(EQ-5D-5L) reduced ceiling effects of the 3-level EQ-5D
(EQ-5D-3L) and improved the discriminatory power and
convergent validity. In our study, broad use of 4 of the 5
Levels of the EQ-5D-5L suggests that it could provide
higher discriminative power than the standard EQ-5D-3L
in COPD, although the most severe category appears to be
rarely utilized. A previous study showed that EQ-5D-3L
index score (both UK and US) failed to differ across COPD
severity stages [35]. The mean EQ-5D-5L index score sig-
nificantly decreases as COPD severity deteriorates, particu-
larly in the advanced stages of disease (Table 3), which may
suggest better discriminatory power of EQ-5D-5L than
EQ-5D-3L to distinguish COPD patients of different sever-
ity. Similar to studies of the EQ-5D-3L in COPD, self-care
is the dimension least affected by COPD [39,40]. In accord-
ance with a study by Punekar et al. [40], about 80% of
COPD patients reported no problems in self-care. As the
severity of COPD increased, COPD patients reported more
problems with mobility, self-care, and usual activities.
However, pain/discomfort and anxiety/depression tended
not to differ by disease severity using the EQ-5D-5L or the
PROMIS. Our study also suggested that EQ-5D-5L index
scores were less able to discriminate among patients with
milder disease, i.e. GOLD grades 1 and 2. This is consistent
with a previous study by Antonelli-Incalzi et al. who
observed that health status dramatically declined when
predicted FEV1 was 49% or less (upper limit of GOLD
grade 3) [41]. Alternatively, the lack of discrimination
between grade 1 and 2 may also suggest that the EQ-5D-
5L descriptive system does not entirely address some of
the limitations of the three-level EQ-5D [39], assuming
there is a meaningful difference in self-reported health
based on GOLD grades 1 and 2. Unlike the EQ-5D index
score which is derived based on the five dimensions using
population preference weights, the EQ-VAS provides a
direct rating of health from the patient’s point of view.
Consistent with previous reports [35], EQ-VAS had a
more monotonic relationship with disease severity and
better ability to discriminate according to disease severity
compared to EQ-5D index.
Among the PROMIS subscales, physical functioning
was most strongly associated with disease grades and
measures of breathing difficulty and functioning. Only
physical function (P-PF), depression (P-D), fatigue (P-F),
and social roles (P-SR) varied significantly across COPD
grades and the magnitude of differences in the PROMIS
scores of depression and fatigue across different GOLDgrades were smaller than half of their SD, a commonly used
cutoff for interpreting important differences in HRQL
scores [42]. Anxiety, sleep, and pain domains of PROMIS,
although moderately related to other HRQL measurements
and dyspnea scores (mainly FACIT-Dyspnea), did not vary
by COPD GOLD grade. The lack of correlation between
pain, anxiety, and sleep disturbance and the degree of
COPD severity does not preclude the importance of these
HRQL parameters in COPD patients. In fact, it has been
reported that 35%, 37% and 51% of advanced COPD pa-
tients suffer from sleep disturbance, pain and anxiety, re-
spectively, arguably among the most prevalent symptoms
associated with advanced COPD [43]. Despite the inability
of these domains to discriminate patients with different
level of airflow limitation, the domains present convergent
validity and it suggests that they may capture patient-
reported outcomes other than those associated with spir-
ometry. In addition, the observation that the parameters of
physical or physiological measures (dyspnea scores; mobil-
ity, self-care and usual activities in EQ-5D-5L; physical
function in PROMIS) deteriorate more with the increase in
COPD severity, as compared to psychosocial measures
(anxiety/depression in EQ-5D-5L; anxiety, depression and
social roles in PROMIS), suggests the possibility of adapa-
tion and coping mechanisms developed in COPD patients
as the disease severity progresses, which is often observed
with chronic illnesses and disabling conditions [44].
EQ-5D and PROMIS, both generic measures of HRQL,
are distinctive in several ways. While EQ-5D index and
VAS scores both provide summary scores for evaluating
general health status as a whole, PROMIS describes differ-
ent aspect of health status individually using domain
scores. The domains of anxiety, depression, and pain are
apparently covered by both of the measures, but it is argu-
able if fatigue (PROMIS) overlaps with pain/discomfort
(EQ-5D), as well as the extent of overlap between physical
functioning, fatigue, sleep disturbance, or social roles
(PROMIS) and mobility, self-care, or usual activities (EQ-
5D). EQ-5D index-based scores are generated from soci-
etal preferences for health that can be applied to economic
evaluations. Although PROMIS-43 does not include global
items and was not designed as a preference-based measure
as EQ-5D, at least one scoring function is available to con-
vert PROMIS selected domain scores into a single index
value by mapping onto the EQ-5D [45]. Comparing to
PROMIS, EQ-5D is presumably briefer to administer as it
contains 6 items (including VAS) rather than 43, but the
PROMIS-43 contains more items in each domain, thereby
providing the potential of a higher level of precision and
sensitity than EQ-5D. Alternatively, even briefer short-
form versions of the PROMIS are available.
This study has several limitations. Since patients did not
complete EQ-5D-3L, we could not directly determine
whether the EQ-5D-5L improves upon the properties of
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http://www.biomedcentral.com/1471-2288/14/78the EQ-5D-3L in COPD. In addition, longitudinal data are
needed to examine and compare the responsiveness of the
measures to detect meaningful change following interven-
tions. Lastly, in our study, patients with more severe
COPD (GOLD 3 and 4) were younger than those with
milder disease, which was contrary to our expectation but
may be due to the eligibility of study participation or pos-
sibly a survivor effect. The representativeness of patients
included in this analysis could also be restricted by the
relatively low response rate (36%) for participating in the
in-person evaluations. Age is a known factor that could
confound the association between HRQL and disease se-
verity [7]. In order to rule out the confounding effect, we
also conducted an analysis of covariance (ANCOVA) to
control for age when comparing the responses in EQ-5D,
PROMIS domain scores, dyspnea measures, and 6MWD
among patients with different GOLD grades (data not
shown). Similar results (F-statistic and significance level)
were found as in Table 3 after controlling for age effect,
except that the discriminative ability of 6MWD and PRO-
MIS sleep disturbance (P-SD) to distinguish COPD pa-
tients of different severity was improved.
Conclusions
In summary, our study provides evidence to support val-
idity of EQ-5D-5L and PROMIS-43 to assess HRQL in
patients with COPD. The measures indicated that
patient-reported physical function and social activities
decrease with level of lung function by GOLD grade, but
not pain, mental health, sleep or fatigue. Future research
using a longitudinal design will help to further under-
stand the strengths and limitations of these measures in
assessing outcomes in COPD patients.
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